PLI Scheme for Bulk Drugs
-
Objective: To attain self-reliance and reduce import dependence in critical Key Starting Materials (KSMs)/Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India.
-
Under the Scheme, financial incentives shall be given based on threshold investment and domestic sales made by selected applicants for the eligible products.
-
Duration: FY 2020-21 to FY 2029-30
What are APIs? It is any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or direct effect in diagnosis, cure, treatment or prevention of disease.